{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:50:05Z","timestamp":1782514205730,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T00:00:00Z","timestamp":1582848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pregabalin is an anticonvulsive, analgesic and anxiolytic medication. The typical side effects include dizziness, somnolence and weight gain. Few studies or case reports have demonstrated psychiatric side effects resulting from its use.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>We present a patient who suffered visual hallucinations and agitation associated with an increase in pregabalin dose, resolving completely after pregabalin discontinuation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Acute visual hallucinations should be considered in the clinical spectrum of very rare side effects of pregabalin use, especially at higher doses. Tapered discontinuation of the medication can improve and resolve symptoms.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40360-020-0395-6","type":"journal-article","created":{"date-parts":[[2020,2,28]],"date-time":"2020-02-28T14:02:43Z","timestamp":1582898563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pregabalin induced visual hallucinations \u2013 a rare adverse reaction"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-712X","authenticated-orcid":false,"given":"Georgios","family":"Mousailidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basavaraja","family":"Papanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Salmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Sein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qutaiba","family":"Al-Hillawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,28]]},"reference":[{"key":"395_CR1","doi-asserted-by":"publisher","first-page":"661","DOI":"10.2165\/11536200-000000000-00000","volume":"49","author":"H Bockbrader","year":"2010","unstructured":"Bockbrader H, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49:661\u20139.","journal-title":"Clin Pharmacokinet"},{"key":"395_CR2","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s00228-010-0853-y","volume":"66","author":"S Schwan","year":"2010","unstructured":"Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin \u2013 results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947\u201353.","journal-title":"Eur J Clin Pharmacol"},{"key":"395_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2165\/11203750-000000000-00000","volume":"26","author":"K McKeage","year":"2009","unstructured":"McKeage K, Keam S. Pregabalin: in the treatment of postherpetic neuralgia. Drugs Aging. 2009;26:883\u201392.","journal-title":"Drugs Aging"},{"key":"395_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5350\/KPB-BCP201121110","volume":"21","author":"I Yargic","year":"2011","unstructured":"Yargic I, Ozdemiroglu F. Pregabalin abuse: a case report. Klinik Psikofarmakoloji B\u00fclteni-Bull Clin Psychopharmacol. 2011;21:64\u20136.","journal-title":"Klinik Psikofarmakoloji B\u00fclteni-Bull Clin Psychopharmacol"},{"issue":"10","key":"395_CR5","first-page":"605","volume":"110","author":"F Filipetto","year":"2010","unstructured":"Filipetto F, Zipp C, Coren J. Potential for pregabalin abuse or diversion after past drug-seeking behavior. J Am Osteopath Assoc. 2010;110(10):605\u20137.","journal-title":"J Am Osteopath Assoc"},{"key":"395_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/01.jcp.0000155820.74832.b0","volume":"25","author":"R Pohl","year":"2005","unstructured":"Pohl R, Feltner D, Fieve R, Pande A. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151\u20138.","journal-title":"J Clin Psychopharmacol"},{"key":"395_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.pain.2010.04.013","volume":"150","author":"R Baron","year":"2010","unstructured":"Baron R, Freynhagen R, Tolle T, Cloutier C, Leon T, Murphy T, Philips K, A0081007 investigators. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain. 2010;150:420\u20137.","journal-title":"Pain"},{"key":"395_CR8","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","volume":"52","author":"G Zaccara","year":"2011","unstructured":"Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826\u201336.","journal-title":"Epilepsia"},{"key":"395_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.seizure.2006.02.004","volume":"15","author":"I Olaizola","year":"2006","unstructured":"Olaizola I, Ellger T, Young P, B\u00f6sebeck F, Evers S, Kelinghaus C. Pregabalin-associated acute psychosis and epileptiform EEG-changes. Seizure. 2006;15:208\u201310.","journal-title":"Seizure"},{"key":"395_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1590\/S0004-282X2012001200012","volume":"70","author":"J Pedroso","year":"2012","unstructured":"Pedroso J, Nakama G, Carneiro-Filho M, Barsottini O. Delirium, psychosis, and visual hallucinations induced by pregabalin. Arq Neuropsiquiatr. 2012;70:960\u20131.","journal-title":"Arq Neuropsiquiatr"},{"issue":"10","key":"395_CR11","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1093\/brain\/aww196","volume":"139","author":"Z Chen","year":"2016","unstructured":"Chen Z, Lusicic A, O\u2019Brien TJ, Velakoulis D, Adams SJ, Kwan P. Psychotic disorders induced by antiepileptic drugs in people with epilepsy. Brain. 2016;139(10):2668\u201378.","journal-title":"Brain"},{"key":"395_CR12","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1177\/070674370204701017","volume":"47","author":"K Jablonowski","year":"2002","unstructured":"Jablonowski K, Margolese H, Chouinard G. Gabapentin induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Can J Psychiatr. 2002;47:975\u20136.","journal-title":"Can J Psychiatr"},{"key":"395_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1053\/seiz.2001.0594","volume":"11","author":"C Kellinghaus","year":"2002","unstructured":"Kellinghaus C, Dziewas R, Ludemann P. Tiagabine-related nonconvulsive status epilepticus in partial epilepsy: three case reports and a review of the literature. Seizure. 2002;11:243\u20139.","journal-title":"Seizure"},{"issue":"4","key":"395_CR14","doi-asserted-by":"publisher","first-page":"436.e1","DOI":"10.1016\/j.genhosppsych.2011.11.004","volume":"34","author":"C Hickey","year":"2012","unstructured":"Hickey C, Thomas B. Delirium secondary to pregabalin. Gen Hosp Psychiatry. 2012;34(4):436.e1\u20132.","journal-title":"Gen Hosp Psychiatry"},{"key":"395_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/01.wnf.0000265979.03198.33","volume":"32","author":"C Solaro","year":"2009","unstructured":"Solaro C, Tanganelli P. Acute delirium in patients with multiple sclerosis treated with pregabalin. Clin Neuropharmacol. 2009;32:236\u20137.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"395_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/ncn3.48","volume":"1","author":"N Mezaki","year":"2013","unstructured":"Mezaki N, Tomohiko I, Tetsutaro O, Ryoko T, Osamu O, Takayoshi S. Patient with insidious hypoactive delirium associated with pregabalin. Neurol Clin Neurosci. 2013;1(5):177\u20138.","journal-title":"Neurol Clin Neurosci"},{"key":"395_CR17","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/bja\/aeu293","volume":"114","author":"B Mishriky","year":"2015","unstructured":"Mishriky B, Waldron N, Habib A. Impact of pregabalin on acute and persistent postoperative pain: a systematic review and metaanalysis. Br J Anaesth. 2015;114:10\u201331.","journal-title":"Br J Anaesth"},{"key":"395_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","volume":"73","author":"C Taylor","year":"2007","unstructured":"Taylor C, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel \u03b12-\u03b4 (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007;73:137\u201350.","journal-title":"Epilepsy Res"},{"issue":"4","key":"395_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/24750573.2018.1452523","volume":"28","author":"I Gundogmus","year":"2018","unstructured":"Gundogmus I, Karagoz A, Algul A. Firstepisode psychosis induced by pregabalin withdrawal: a case report. Psychiatry Clin Psychopharmacol. 2018;28(4):461\u20133.","journal-title":"Psychiatry Clin Psychopharmacol"},{"issue":"9","key":"395_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1007\/s40261-016-0421-z","volume":"36","author":"J Bossard","year":"2016","unstructured":"Bossard J, Pont\u00e9 C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. Disproportionality analysis for the assessment of abuse and dependence potential of pregabalin in the French pharmacovigilance database. Clin Drug Investig. 2016;36(9):735\u201342.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"395_CR21","first-page":"320","volume":"51","author":"J Nordgaard","year":"2013","unstructured":"Nordgaard J, Jurgens G. A case of pregabalin abuse. Clin Toxicol. 2013;51(4):320.","journal-title":"Clin Toxicol"},{"key":"395_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/bmj.288.6424.1135","volume":"288","author":"H Ashton","year":"1984","unstructured":"Ashton H. Benzodiazepine withdrawal: an unfinished story. Br Med J (Clin Res ed). 1984;288:1135.","journal-title":"Br Med J (Clin Res ed)"},{"key":"395_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1177\/0269881111405360","volume":"26","author":"S Hadley","year":"2012","unstructured":"Hadley S, Mandel F, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26:461\u201370.","journal-title":"J Psychopharmacol"},{"key":"395_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s12325-012-0061-5","volume":"29","author":"R Guglielmo","year":"2012","unstructured":"Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29:947\u201357.","journal-title":"Adv Ther"},{"issue":"4","key":"395_CR25","first-page":"530","volume":"63","author":"N Sawant","year":"2013","unstructured":"Sawant N, Bokdawala R. Pregabalin in the treatment of Charles bonnet syndrome. J Pak Med Assoc. 2013;63(4):530\u20131.","journal-title":"J Pak Med Assoc"},{"issue":"2","key":"395_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4088\/PCC.08l00647","volume":"11","author":"A Tripp","year":"2009","unstructured":"Tripp A, Golden S. Transient complex visual hallucinations with venlafaxine treatment: a case report. Prim Care Companion J Clin Psychiatry. 2009;11(2):83.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"4","key":"395_CR27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.4088\/JCP.08l04627","volume":"70","author":"M Jacob","year":"2009","unstructured":"Jacob M, Ash P. Venlafaxine-induced complex visual hallucinations in a 17-year-old boy. J Clin Psychiatry. 2009;70(4):601\u20133.","journal-title":"J Clin Psychiatry"},{"key":"395_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2004.07.010","volume":"61","author":"M Bialer","year":"2004","unstructured":"Bialer M, Johannessen S, Kupferberg H, Levy R, Perrucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the seventh EILAT conference (EILAT VII). Epilepsy Res. 2004;61:1\u201348.","journal-title":"Epilepsy Res"},{"issue":"1","key":"395_CR29","first-page":"4","volume":"47","author":"D Javitt","year":"2010","unstructured":"Javitt D. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci. 2010;47(1):4\u201316.","journal-title":"Isr J Psychiatry Relat Sci"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-020-0395-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0395-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:19:45Z","timestamp":1614385185000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-0395-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["395"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-0395-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,28]]},"assertion":[{"value":"5 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have obtained full permission from the patient to disclose the current data anonymised and to utilise them for a scientific publication and for the advancement of science.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have obtained informed consent for publication in written form from the patient to disclose the current data anonymised and to utilize them for a scientific publication and for the advancement of science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}